Opko Health director granted 30K stock options

OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation. The options have an exercise price of $1.42 per share, become exercisable starting on 2027-06-18, and expire on 2036-06-17. Following this grant, he holds 30,000 options directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider PAGANELLI JOHN A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Key Figures

Options granted: 30,000 options Exercise price: $1.42 per share Post-grant derivative holdings: 30,000 options +2 more

5 metrics

Options granted 30,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.42 per share Conversion or exercise price of stock options

Post-grant derivative holdings 30,000 options Total derivative shares following transaction

Exercise start date June 18, 2027 Date options become exercisable

Expiration date June 17, 2036 Options expiration

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, derivative, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

exercise price financial

"conversion_or_exercise_price: "1.4200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

total shares following transaction financial

"total_shares_following_transaction: "30000.0000""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OPKO Health (OPK) director John A. Paganelli report on this Form 4?

John A. Paganelli reported receiving a grant of stock options for 30,000 shares of OPKO Health common stock. This is a compensation-related award, not an open-market stock purchase or sale, and gives him the right to buy shares at a fixed price later.

How many OPKO Health (OPK) stock options were granted to John A. Paganelli?

He was granted stock options covering 30,000 shares of OPKO Health common stock. These options are reported as a single derivative transaction and represent his total derivative holdings following the grant, according to the filing’s post-transaction share information.

What is the exercise price of John A. Paganelli’s OPKO Health (OPK) stock options?

The options have an exercise price of $1.42 per share. This means he can buy OPKO Health common stock at $1.42 per share when the options are exercisable, regardless of the market price at that time.

When do John A. Paganelli’s OPKO Health (OPK) stock options become exercisable and when do they expire?

The options become exercisable on June 18, 2027, and expire on June 17, 2036. After the expiration date, he can no longer use these options to buy OPKO Health common stock at the stated exercise price.

Is John A. Paganelli buying or selling OPKO Health (OPK) shares in this Form 4?

He is not buying or selling shares in the market. The Form 4 reports a grant or award acquisition of stock options, a compensation-related derivative giving the right to purchase 30,000 OPKO Health shares at $1.42 in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 05:36 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAGANELLI JOHN A

(Last)

(First)

(Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI

FLORIDA

33137

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.42	06/18/2026		A		30,000		06/18/2027	06/17/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

	Steven D. Rubin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR